<DOC>
	<DOCNO>NCT01376167</DOCNO>
	<brief_summary>The purpose two part study test safety efficacy Tafenoquine ( Cholorquine ) radical cure Plasmodium vivax ( P.vivax ) malaria relative control Chloroquine.Part 1 aim select efficacious well tolerate dose co-administered Chloroquine . Part 2 investigate safety efficacy select dose ( 300 mg tafenoquine ) treatment radical cure Plasmodium Vivax Malaria .</brief_summary>
	<brief_title>Ph 2B/3 Tafenoquine ( TFQ ) Study Prevention Vivax Relapse</brief_title>
	<detailed_description>Plasmodium vivax represent 50-80 % malarial case Latin America South East Asia . It able establish dormant liver stage call hypnozoite . Hypnozoite activation initial infection cause relapse . Currently widely available drug primaquine require administration 14 day , result poor compliance treatment failure . Tafenoquine ( 8-aminoquinoline anti-malarial drug ) show possess activity stage plasmodium life cycle , include dormant stage liver . This multi-centre , double dummy , double blind , parallel group , randomize , active control study conduct two part . For part , subject treat Chloroquine day 1 3 ( 600mg , 600mg , 300mg ) treat blood stage vivax malaria . Part 1 include least 324 subject part 2 least 600 subject . Part 1 6 treatment arm , arm 1 4 contain different dos Tafenoquine ( 50mg , 100mg , 300mg , 600mg ) dose day 1 2 , arm 5 contains primaquine ( 15mg ) dose 14 day ( day 2-15 ( 15mg ) ) arm 6 contains chloroquine . The aim find dose Tafenoquine meet define dose criterion . Based Part 1 efficacy safety , single Tafenoquine dose ( 300 mg ) study pivotal Part 2 . Part 2 contains 3 treatment arm one select Tafenoquine dose ( 300 mg ) , second arm 15mg Primaquine dose 14 day final arm contains chloroquine dose day 1-3 ( 600mg , 600mg , 300mg ) . Therefore Part 1 , Part 2 subject receive Chloroquine . The aim Part 2 investigate safety efficacy select Tafenoquine/Chloroquine dose treatment radical cure Plasmodium vivax malaria . In addition Primary Secondary endpoint state also collect ; efficacy endpoint ( gametocyte clearance time , Recrudescence define Plasmodium vivax parasitemia occur Day 29 ( blood stage treatment failure ) , Incidence Plasmodium falciparum malaria Incidence recrudescence new Plasmodium vivax infection , determine Polymerase Chain Reaction ( PCR ) , safety endpoint ( clinically relevant haemolysis lead drop haemoglobin / haematocrit complication thereof ( required transfusion , acute renal failure ) , change methaemoglobin , gastrointestinal ( GI ) tolerability - incidence abdominal pain , heartburn , diarrhoea , constipation , nausea vomit ophthalmic safety - incidence corneal deposit , retinal visual field abnormality . Data collect four centre . Additionally , incidence severity adverse event abnormal laboratory observation present ) .Pharmacokinetic endpoint ( Population pharmacokinetic parameter tafenoquine include limited oral clearance ( CL/F ) volume distribution ( V/F ) Pharmacokinetic/Pharmacodynamic endpoint ( e.g . tafenoquine plasma concentration ) select Pharmacodynamic endpoint ( e.g . relapse efficacy , change methaemoglobin ) appropriate , explore .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Tafenoquine</mesh_term>
	<criteria>Positive Giemsa smear P. vivax Parasite density &gt; 100 &lt; 200,000/μL ≥16 year A female eligible nonpregnant , nonlactating : nonchild bear potential define : postmenopausal ( 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum follicle stimulate hormone &gt; 40 mIU/mL ) , premenopausal hysterectomy bilateral oophorectomy ( removal ovary ) bilateral tubal ligation medical report verification , negative pregnancy test , childbearing potential , negative serum pregnancy test screening , agree comply one follow treatment stage study period 90 day stop study drug : Use oral contraceptive , either combined progestogen alone used conjunction double barrier method define Use intrauterine device document failure rate &lt; 1 % per year Use depo provera injection ( part 2 ) Double barrier method consist spermicide either condom diaphragm Male partner sterile prior female subject 's entry study sole sexual partner female . Complete abstinence intercourse 2 week prior administration study drug , throughout study period 90 day stop study drug . A signed date informed consent obtain subject subject 's legal representative prior screen . NB Assent obtain subject &lt; 18 year , applicable write oral witnessed consent obtain parent guardian . The subject able understand comply protocol requirement , instruction protocolstated restriction likely complete study plan . Willing hospitalize 3 day return clinic followup visit include Day 180 QTc &lt; 450 msec screening , base single QTcF value screening ( part 1 ) average triplicate Electrocardiogram obtain brief recording period machine manual overread first &gt; 450 msec . Mixed malaria infection ( e.g . identify Giemsastained smear rapid diagnostic test ) Severe vivax malaria define World Health Organisation criterion . Severe vomit ( food inability take food previous 8 hour ) Screening haemoglobin concentration &lt; 7 g/dL . Glucose 6phosphate dehydrogenase deficiency , assess quantitative spectrophotometric phenotype assay : Part 1 Males : Any subject enzyme level &lt; 70 % site median value Glucose 6phosphate dehydrogenase normal exclude . Females : Those female screen Hb ≥ 10 g/dL exclude enzyme level &lt; 70 % site median value Glucose 6Phosphate dehydrogenase normal . hose female Hb ≥7 &lt; 10 g/dL exclude enzyme level &gt; 90 % site median value Glucose 6Phosphate dehydrogenase normal . Part 2 Any subject enzyme level &lt; 70 % site median value Glucose 6phosphate dehydrogenase normal exclude Liver function test alanine transaminase &gt; 2x Upper Limit Normal Any clinically significant concurrent illness ( e.g . pneumonia , septicaemia ) , preexist condition ( e.g . renal disease , malignancy ) , condition may affect absorption study medication ( e.g . vomit severe diarrhea ) clinical sign symptom severe cardiovascular disease ( e.g . uncontrolled congestive heart failure severe coronary artery disease ) . These abnormality may identify screen history physical laboratory examination . Subject take antimalarial ( e.g . ACT , mefloquine , primaquine , chloroquine ) drug antimalarial activity within past 30 day history . History allergy chloroquine , mefloquine , tafenoquine , primaquine 4 8aminoquinolines . Any contraindication chloroquine primaquine administration include history porphyria , psoriasis epilepsy ( please refer chloroquine primaquine locally approve prescribe information ) . Subject previously receive study medication protocol ( part ) receive treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . History illicit drug abuse heavy alcohol intake within 6 month study . Subjects take likely require use medication prohibit medication list include follow class : Histamine2 blocker antacid . Drugs haemolytic potential . Drugs know prolong QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>